Aclaris Therapeutics (ACRS) Other Operating Expenses (2016 - 2026)

Aclaris Therapeutics' Other Operating Expenses history runs 11 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• In Q1 2026, Other Operating Expenses fell 1.54% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $9.6 million (down 90.63% YoY), while the FY2025 annual figure was $9.6 million, down 90.86% from the prior year.
• Other Operating Expenses was $1.8 million for Q1 2026 at Aclaris Therapeutics, down from $1.9 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $94.9 million in Q4 2024 to a low of -$13.2 million in Q4 2023.
• Historically, Other Operating Expenses has averaged $7.7 million across 5 years, with a median of $2.1 million in 2024.
• Biggest YoY gain for Other Operating Expenses was 2475.56% in 2023; the steepest drop was 253.74% in 2023.
• A 5-year view of Other Operating Expenses shows it stood at $8.6 million in 2022, then sank by 253.74% to -$13.2 million in 2023, then soared by 816.65% to $94.9 million in 2024, then sank by 98.03% to $1.9 million in 2025, then retreated by 4.33% to $1.8 million in 2026.
• The last three Other Operating Expenses figures came in at $1.8 million (Q1 2026), $1.9 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.